These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 10086436)

  • 1. Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic.
    Nolan CM; Goldberg SV; Buskin SE
    JAMA; 1999 Mar; 281(11):1014-8. PubMed ID: 10086436
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of age-related isoniazid hepatotoxicity during treatment of latent tuberculosis infection.
    Aziz H; Shubair M; Debari VA; Ismail M; Khan MA
    Curr Med Res Opin; 2006 Jan; 22(1):217-21. PubMed ID: 16393447
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatotoxicity of rifampin-pyrazinamide and isoniazid preventive therapy and tuberculosis treatment.
    van Hest R; Baars H; Kik S; van Gerven P; Trompenaars MC; Kalisvaart N; Keizer S; Borgdorff M; Mensen M; Cobelens F
    Clin Infect Dis; 2004 Aug; 39(4):488-96. PubMed ID: 15356811
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Isoniazid hepatotoxicity associated with treatment of latent tuberculosis infection: a 7-year evaluation from a public health tuberculosis clinic.
    Fountain FF; Tolley E; Chrisman CR; Self TH
    Chest; 2005 Jul; 128(1):116-23. PubMed ID: 16002924
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pyrazinamide and rifampin vs isoniazid for the treatment of latent tuberculosis: improved completion rates but more hepatotoxicity.
    McNeill L; Allen M; Estrada C; Cook P
    Chest; 2003 Jan; 123(1):102-6. PubMed ID: 12527609
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Baseline abnormal liver function tests are more important than age in the development of isoniazid-induced hepatoxicity for patients receiving preventive therapy for latent tuberculosis infection.
    Gray EL; Goldberg HF
    Intern Med J; 2016 Mar; 46(3):281-7. PubMed ID: 26648478
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatotoxicity of pyrazinamide: cohort and case-control analyses.
    Chang KC; Leung CC; Yew WW; Lau TY; Tam CM
    Am J Respir Crit Care Med; 2008 Jun; 177(12):1391-6. PubMed ID: 18388355
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatotoxicity During Isoniazid Preventive Therapy and Antiretroviral Therapy in People Living With HIV With Severe Immunosuppression: A Secondary Analysis of a Multi-Country Open-Label Randomized Controlled Clinical Trial.
    Ngongondo M; Miyahara S; Hughes MD; Sun X; Bisson GP; Gupta A; Kumwenda J; Lavenberg JA; Torres TS; Nyirenda M; Kidonge KK; Hosseinipour MC;
    J Acquir Immune Defic Syndr; 2018 May; 78(1):54-61. PubMed ID: 29406428
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk factors of isoniazid-induced hepatotoxicity in Tunisian tuberculosis patients.
    Ben Fredj N; Gam R; Kerkni E; Chaabane A; Chadly Z; Boughattas N; Aouam K
    Pharmacogenomics J; 2017 Jul; 17(4):372-377. PubMed ID: 27089936
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adherence to nine-month isoniazid for latent tuberculosis infection in healthcare workers: a prospective study in a tertiary hospital.
    Chung SJ; Lee H; Koo GW; Min JH; Yeo Y; Park DW; Park TS; Moon JY; Kim SH; Kim TH; Sohn JW; Yoon HJ
    Sci Rep; 2020 Apr; 10(1):6462. PubMed ID: 32296096
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a multicenter clinical trial.
    Jasmer RM; Saukkonen JJ; Blumberg HM; Daley CL; Bernardo J; Vittinghoff E; King MD; Kawamura LM; Hopewell PC;
    Ann Intern Med; 2002 Oct; 137(8):640-7. PubMed ID: 12379063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Isoniazid-related fatal hepatitis.
    Millard PS; Wilcosky TC; Reade-Christopher SJ; Weber DJ
    West J Med; 1996 Jun; 164(6):486-91. PubMed ID: 8764622
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Isoniazid-induced hepatotoxicity in children with latent tuberculosis infection.
    Devrim İ; Devrim F; Bayram N; Aktürk H; Aksay A; Can D; Apa H
    Minerva Pediatr (Torino); 2021 Apr; 73(2):184-187. PubMed ID: 26377643
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adverse events with 4 months of rifampin therapy or 9 months of isoniazid therapy for latent tuberculosis infection: a randomized trial.
    Menzies D; Long R; Trajman A; Dion MJ; Yang J; Al Jahdali H; Memish Z; Khan K; Gardam M; Hoeppner V; Benedetti A; Schwartzman K
    Ann Intern Med; 2008 Nov; 149(10):689-97. PubMed ID: 19017587
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Under-reporting and Poor Adherence to Monitoring Guidelines for Severe Cases of Isoniazid Hepatotoxicity.
    Hayashi PH; Fontana RJ; Chalasani NP; Stolz AA; Talwalkar JA; Navarro VJ; Lee WM; Davern TJ; Kleiner DE; Gu J; Hoofnagle JH;
    Clin Gastroenterol Hepatol; 2015 Sep; 13(9):1676-82.e1. PubMed ID: 25724701
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of N-acetyltransferase 2 and cytochrome P450 2E1 gene polymorphisms with antituberculosis drug-induced hepatotoxicity in Western India.
    Gupta VH; Amarapurkar DN; Singh M; Sasi P; Joshi JM; Baijal R; Ramegowda PH; Amarapurkar AD; Joshi K; Wangikar PP
    J Gastroenterol Hepatol; 2013 Aug; 28(8):1368-74. PubMed ID: 23875638
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Isoniazid-induced acute liver failure during preventive therapy for latent tuberculosis infection.
    Miyazawa S; Matsuoka S; Hamana S; Nagai S; Nakamura H; Nirei K; Moriyama M
    Intern Med; 2015; 54(6):591-5. PubMed ID: 25786447
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatotoxicity from isoniazid and rifampin among children treated for tuberculosis.
    O'Brien RJ; Long MW; Cross FS; Lyle MA; Snider DE
    Pediatrics; 1983 Oct; 72(4):491-9. PubMed ID: 6604257
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Twelve-dose weekly rifapentine plus isoniazid for latent tuberculosis infection: A multicentre randomised controlled trial in Taiwan.
    Sun HY; Huang YW; Huang WC; Chang LY; Chan PC; Chuang YC; Ruan SY; Wang JY; Wang JT
    Tuberculosis (Edinb); 2018 Jul; 111():121-126. PubMed ID: 30029896
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Completion Rate and Safety of Tuberculosis Infection Treatment With Shorter Regimens.
    Cruz AT; Starke JR
    Pediatrics; 2018 Feb; 141(2):. PubMed ID: 29363561
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.